Mallinckrodt has patented a method to identify premature infants at risk for bronchopulmonary dysplasia and likely to benefit from inhaled nitric oxide therapy. By analyzing genetic mutations in nitric oxide synthase genes, the method aims to personalize treatment and avoid unnecessary risks. GlobalData’s report on Mallinckrodt gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mallinckrodt, was a key innovation area identified from patents. Mallinckrodt's grant share as of May 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US12007399B2) outlines a method for identifying premature infants likely to respond positively to inhaled nitric oxide therapy. The method involves obtaining a blood or tissue sample from the infant before treatment, analyzing it for specific genetic mutations in genes encoding nitric oxide synthase, and then determining the presence of these mutations to predict the likelihood of developing bronchopulmonary dysplasia. If the genetic mutation is present, treatment with inhaled nitric oxide is recommended to reduce the risk of bronchopulmonary dysplasia in premature infants under 30 weeks gestational age.
Furthermore, the patent describes a method to avoid risks associated with inhaled nitric oxide therapy in premature infants at risk of bronchopulmonary dysplasia. This method involves testing for specific markers such as plasma nitrate and nitrite concentrations, exhaled nitric oxide levels, and genetic mutations in the endothelial nitric oxide synthase gene. Based on the results, the premature infant is either treated with non-inhaled nitric oxide modalities or with inhaled nitric oxide to reduce the likelihood of bronchopulmonary dysplasia development, depending on the specific markers identified. This approach aims to personalize treatment for premature infants under 30 weeks gestational age, ensuring optimal outcomes while minimizing risks associated with inhaled nitric oxide therapy.
To know more about GlobalData’s detailed insights on Mallinckrodt, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
